Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 11/20 | 0.40 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.37 |
| ▸ | SELE | P16581 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | PRNP | P04156 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460519 | 0.82 | ESR1 (0.39) | ESR1ICAM1SELETSHRDYRK1A | |
| SCHEMBL5462756 | 0.81 | ESR1 (0.39) | ESR1ICAM1SELEESR2CLK1 | |
| SCHEMBL5447565 | 0.80 | GRM1 (0.46) | ESR1CLK1 | |
| SCHEMBL5462763 | 0.79 | KMT2A (0.55) | ESR1TSHRNPSR1ESR2 | |
| SCHEMBL5450964 | 0.78 | FLT3 (0.48) | ESR1DYRK1AMAPK1HTTMAPK10 | |
| SCHEMBL5447596 | 0.78 | GAA (0.48) | ESR1HTT | |
| SCHEMBL5451109 | 0.77 | MEN1 (0.56) | TSHRDYRK1AHTTNPSR1 | |
| SCHEMBL5467623 | 0.76 | KDR (0.42) | ESR1ICAM1SELEESR2 | |
| SCHEMBL5457824 | 0.76 | RAB9A (0.43) | ESR1DYRK1AESR2 | |
| SCHEMBL5458283 | 0.75 | MEN1 (0.43) | DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
| EP-1670804-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC Biotech AG (DE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005023818-A2 | HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | GPC BIOTECH AG (DE) | 2005-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | ESR1 3803/4885ICAM1 662/4885SELE 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.